2Alberti C, Brun-Buisson C, Burchardi H,et al. Epidemiology of sepsis and infection in ICU patients from an international muhicen- tre cohort study. Intensive Care Med,2002,28 : 108-121.
3Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA, 2005,294 : 813-818.
4Dandekar PK, Maglio D, Sutherland CA, et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy, 2003,23 : 988-991.
5Jaruratanasirikul S,Sriwiriyajan S,Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother, 2005,49 : 1337-1339.
6Valtonen M,Tiula E, Backman JT, et al. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother, 2000,45 : 701-704.
7Giles LJ,Jennings AC,Thomson AH,et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafihration. Crit Care Med, 2000,28 : 632-637.
8Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofihralion. Chemotherapy, 2003,49 : 280-286.
9Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother, 1998,42 : 2417-2420.
10Krueger WA,Bulitta J, Kinzig-Schippers M, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother,2005,49: 1881-1889.
